Jacob Moyer, BS

Jacob Moyer, BS, is a graduate researcher at Mayo Clinic.

Articles by Jacob Moyer, BS

Jacob Moyer, BS, graduate researcher, Mayo Clinic; Mark Tyson II, MD, MPH, urologic oncologist, associate professor, urology, Mayo Clinic Alix School of Medicine

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

ByJacob Moyer, BS,Mark D. Tyson, II, MD, MPH

May 1st 2025

Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

ByJacob Moyer, BS

March 19th 2025

Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.

Latest Updated Articles

Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
March 19th 2025
Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH
May 1st 2025

Jacob Moyer, BS

Articles by Jacob Moyer, BS

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

Latest Updated Articles

Trending on OncLive

FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL

Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC

Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL